The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion

AIDS

Volumn 31, Issue 14, 2017, Pages 2007-2016

  Donnell, Deborah ^a,b   Ramos, Eric ^b   Celum, Connie ^b   Baeten, Jared ^b   Dragavon, Joan ^b   Tappero, Jordan ^d   Lingappa, Jairam R ^b,c   Ronald, Allan ^e   Fife, Kenneth ^f   Coombs, Robert W ^b   Frenkel, Lisa ^b   Hendrix, Craig W ^b   McElrath, M Juliana ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e UNIVERSITY OF MANITOBA   (Canada)

^f INDIANA UNIVERSITY   (United States)

Author keywords

early HIV 1 seroconversion; Fiebig stages; HIV 1 RNA; HIV 1 testing; preexposure prophylaxis

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TENOFOVIR; VIRUS RNA; PLACEBO;

ADULT; ARTICLE; FEMALE; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SEROCONVERSION; VIRUS LOAD; VIRUS RESISTANCE; WESTERN BLOTTING; DOUBLE BLIND PROCEDURE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; KENYA; LONGITUDINAL STUDY; ORAL DRUG ADMINISTRATION; PROCEDURES; TIME FACTOR; UGANDA;

ADMINISTRATION, ORAL; ADULT; ANTI-HIV AGENTS; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; KENYA; LONGITUDINAL STUDIES; MALE; PLACEBOS; PRE-EXPOSURE PROPHYLAXIS; RETROSPECTIVE STUDIES; SEROCONVERSION; TIME FACTORS; UGANDA;

EID: 85022056161     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000001577     Document Type: Article

References (39)

1. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo- controlled phase 3 trial. Lancet 2013; 381:2083-2090.
2. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599.
3. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Preexposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 2016; 387:53-60.
4. Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med 2015; 373:2237-2246.
5. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423-434.
6. Baeten JM, Donnell D, Ndase P, MugoNR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410.
7. Lehman DA, Baeten JM, McCoy CO, Weis JF, Peterson D, Mbara G, et al. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis. J Infect Dis 2015; 211:1211-1218.
8. Baeten JM, Donnell D, Mugo NR, Ndase P, Thomas KK, Campbell JD, et al. Single-agent tenofovir versus combination emtricitabine plus tenofovir for preexposure prophylaxis for HIV- 1 acquisition: an update of data from a randomised, doubleblind, phase 3 trial. Lancet Infect Dis 2014; 14:1055-1064.
9. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871-1879.
10. Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 infection. N Engl J Med 2011; 364:1943-1954.
11. Cohen MS, Gay CL, Busch MP, Hecht FM. The detection of acute HIV infection. J Infect Dis 2010; 202 (Suppl 2):S270-277.
12. Laeyendecker O, Redd AD, Nason M, Longosz AF, Karim QA, Naranbhai V, et al. Antibody maturation in women who acquire HIV infection while using antiretroviral preexposure prophylaxis. J Infect Dis 2015; 212:754-759.
13. Baeten JM, Celum C. Antiretroviral preexposure prophylaxis for HIV prevention. N Engl J Med 2013; 368:83-84.
14. Ndase P, Celum C, Kidoguchi L, Ronald A, Fife KH, Bukusi E, et al. Frequency of false positive rapid HIV serologic tests in African men and women receiving PrEP for HIV prevention: implications for programmatic roll-out of biomedical interventions. PLoS One 2015; 10:e0123005.
15. Mujugira A, Baeten JM, Donnell D, Ndase P, Mugo NR, Barnes L, et al. Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral preexposure prophylaxis for HIV-1 prevention. PLoS One 2011; 6:e25828.
16. Keller MJ, Madan RP, Torres NM, Fazzari MJ, Cho S, Kalyoussef S, et al. A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One 2011; 6:e16475.
17. Karim SS, Kashuba AD, Werner L, Karim QA. Drug concentrations after topical and oral antiretroviral preexposure prophylaxis: implications for HIV prevention in women. Lancet 2011; 378:279-281.
18. Masciotra S, McDougal JS, Feldman J, Sprinkle P, Wesolowski L, Owen SM. Evaluation of an alternative HIV diagnostic algorithm using specimens from seroconversion panels and persons with established HIV infections. J Clin Virol 2011; 52 (Suppl 1): S17-22.
19. Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 2011; 3:112re114.
20. Hendrix CW, Andrade A, Bumpus NN, Kashuba AD, Marzinke MA, Moore A, et al. Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066). AIDS Res Hum Retroviruses 2016; 32:32-43.
21. Suntharasamai P, Martin M, Choopanya K, Vanichseni S, Sangkum U, Tararut P, et al. Assessment of oral fluid HIV test performance in an HIV pre-exposure prophylaxis trial in Bangkok, Thailand. PLoS One 2015; 10:e0145859.
22. Curtis KA, Kennedy MS, Luckay A, Cong ME, Youngpairoj AS, Zheng Q, et al. Delayed maturation of antibody avidity but not seroconversion in rhesus macaques infected with simian HIV during oral preexposure prophylaxis. J Acquir Immune Defic Syndr 2011; 57:355-362.
23. Garcia-Lerma JG, Otten RA, Qari SH, Jackson E, Cong ME, Masciotra S, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 2008; 5:e28.
24. Chirwa LI, Johnson JA, Niska RW, Segolodi TM, Henderson FL, Rose CE, et al. CD4(R) cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxis. AIDS 2014; 28:223-226.
25. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411-422.
26. Grossman H, Anderson P, Grant R, Gandhi M, Mohri H, Markowitz M. Newly acquired HIV-1 infection with multidrug resistant (MDR) HIV-1 in a patient on TDF/FTC-based PrEP. R4P. Chicago; 2016.
27. Knox D, Tan D, Harrigan P, Anderson P. HIV-1 infection with multiclass resistance despite preexposure prophylaxis (PrEP). Conference on Retroviruses and Opportunistic Infections; 2016.
28. Robb ML, Eller LA, Kibuuka H, Rono K, Maganga L, Nitayaphan S, et al. Prospective study of acute HIV-1 infection in adults in East Africa and Thailand. N Engl J Med 2016; 374:2120-2130.
29. Rutstein SE, Pettifor AE, Phiri S, Kamanga G, Hoffman IF, Hosseinipour MC, et al. Incorporating acute HIV screening into routine HIV testing at sexually transmitted infection clinics, and HIV Testing and Counseling Centers in Lilongwe, Malawi. J Acquir Immune Defic Syndr 2016; 71:272-280.
30. Ananworanich J, Sacdalan CP, Pinyakorn S, Chomont N, de Souza M, Luekasemsuk T, et al. Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. J Virus Eradication 2016; 2:43-48.
31. Schacker TW, Hughes JP, Shea T, Coombs RW, Corey L. Biological and virologic characteristics of primary HIV infection. Ann Intern Med 1998; 128:613-620.
32. Sarr AD, Eisen G, Gueye-Ndiaye A, Mullins C, Traore I, Dia MC, et al. Viral dynamics of primary HIV-1 infection in Senegal, West Africa. J Infect Dis 2005; 191:1460-1467.
33. Mayaphi SH, Martin DJ, Quinn TC, Laeyendecker O, Olorunju SA, Tintinger GR, et al. Detection of acute and early HIV-1 infections in an HIV hyper-endemic area with limited resources. PLoS One 2016; 11:e0164943.
34. Bacon O, Vittinghoff E, Cohen S, Doblecki-Lewis S, Coleman M, Buchbinder S, et al. HIV testing in the US PrEP demonstration project: rEIAvs. Antigen/antibody vs. RNA. Conference of Retroviral and Opportunistic Infections. Boston; 2016.
35. Delaugerre C, Charreau I, Mahjoub N, Cua E, Pasquet A, Hall N, et al. Usefulness of rapid tests for HIV diagnosis in the ANRS IPERGAY trial. Conference on Retroviruses and Opportunistic Infections. Boston; 2016.
36. Busch MP, Satten GA. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am J Med 1997; 102 (5B):117-124discussion 125-116.
37. Ciesielski CA, Metler RP. Duration of time between exposure and seroconversion in healthcare workers with occupationally acquired infection with human immunodeficiency virus. Am J Med 1997; 102 (5B):115-116.
38. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O'Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS 2016; 30:1973-1983.
39. Ananworanich J, Fletcher JLK, Pinyakorn S, van Griensven F, Vandergeeten C, Schuetz A, et al. A novel acute HIV infection staging system based on 4th generation immunoassay. Retrovirology 2013; 10:56.